These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 29383600

  • 1. The role of surgery in intracranial PCNSL.
    Jahr G, Da Broi M, Holte H, Beiske K, Meling TR.
    Neurosurg Rev; 2018 Oct; 41(4):1037-1044. PubMed ID: 29383600
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Evaluation of Memorial Sloan-Kettering Cancer Center and International Extranodal Lymphoma Study Group prognostic scoring systems to predict Overall Survival in intracranial Primary CNS lymphoma.
    Jahr G, Broi MD, Holte H, Beiske K, Meling TR.
    Brain Behav; 2018 Mar; 8(3):e00928. PubMed ID: 29541540
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study.
    Houillier C, Ghesquières H, Chabrot C, Soussain C, Ahle G, Choquet S, Nicolas-Virelizier E, Bay JO, Vargaftig J, Gaultier C, Touitou V, Martin-Duverneuil N, Cassoux N, Le Garff-Tavernier M, Costopoulos M, Faurie P, Hoang-Xuan K.
    J Neurooncol; 2017 Jun; 133(2):315-320. PubMed ID: 28432587
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Is deep brain involvement in intracranial primary central nervous system lymphoma of importance for penetration of chemotherapeutic agents?
    Meling TR, Latysheva A, Da Broi M, Jahr G, Holte H, Beiske K, Emblem KE.
    Neuroradiology; 2018 Jul; 60(7):703-713. PubMed ID: 29804159
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group.
    Kasenda B, Ihorst G, Schroers R, Korfel A, Schmidt-Wolf I, Egerer G, von Baumgarten L, Röth A, Bloehdorn J, Möhle R, Binder M, Keller U, Lamprecht M, Pfreundschuh M, Valk E, Fricker H, Schorb E, Fritsch K, Finke J, Illerhaus G.
    Leukemia; 2017 Dec; 31(12):2623-2629. PubMed ID: 28559537
    [Abstract] [Full Text] [Related]

  • 11. Role of rituximab in treatment of patients with primary central nervous system lymphoma: a retrospective analysis of the Czech lymphoma study group registry.
    Mocikova H, Pytlik R, Sykorova A, Janikova A, Prochazka V, Vokurka S, Berkova A, Belada D, Campr V, Buresova L, Trneny M, Czech Lymphoma Study Group.
    Leuk Lymphoma; 2016 Dec; 57(12):2777-2783. PubMed ID: 27087066
    [Abstract] [Full Text] [Related]

  • 12. Characteristics and Outcomes of Primary Central Nervous System Lymphoma: A Retrospective Study of 91 Cases in a Chinese Population.
    Mao C, Chen F, Li Y, Jiang X, Liu S, Guo H, Huang L, Wei X, Liang Z, Li W, Tang K.
    World Neurosurg; 2019 Mar; 123():e15-e24. PubMed ID: 30326304
    [Abstract] [Full Text] [Related]

  • 13. The influence of rituximab, high-dose therapy followed by autologous stem cell transplantation, and age in patients with primary CNS lymphoma.
    Madle M, Krämer I, Lehners N, Schwarzbich M, Wuchter P, Herfarth K, Egerer G, Ho AD, Witzens-Harig M.
    Ann Hematol; 2015 Nov; 94(11):1853-7. PubMed ID: 26268792
    [Abstract] [Full Text] [Related]

  • 14. Proposed therapeutic strategy for adult low-grade glioma based on aggressive tumor resection.
    Nitta M, Muragaki Y, Maruyama T, Ikuta S, Komori T, Maebayashi K, Iseki H, Tamura M, Saito T, Okamoto S, Chernov M, Hayashi M, Okada Y.
    Neurosurg Focus; 2015 Jan; 38(1):E7. PubMed ID: 25599276
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A new prognostic score for disease progression and mortality in patients with newly diagnosed primary CNS lymphoma.
    Liu CJ, Lin SY, Yang CF, Yeh CM, Kuan AS, Wang HY, Tsai CK, Gau JP, Hsiao LT, Chen PM, Liu YC, Hong YC, Ko PS, Liu JH, Lin CH.
    Cancer Med; 2020 Mar; 9(6):2134-2145. PubMed ID: 32011103
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Primary central nervous system lymphoma: monocenter, long-term, intent-to-treat analysis.
    Kiewe P, Fischer L, Martus P, Thiel E, Korfel A.
    Cancer; 2008 Apr 15; 112(8):1812-20. PubMed ID: 18318432
    [Abstract] [Full Text] [Related]

  • 20. TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy.
    Munch-Petersen HD, Asmar F, Dimopoulos K, Areškevičiūtė A, Brown P, Girkov MS, Pedersen A, Sjö LD, Heegaard S, Broholm H, Kristensen LS, Ralfkiaer E, Grønbæk K.
    Acta Neuropathol Commun; 2016 Apr 22; 4():40. PubMed ID: 27101868
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.